ReviewLiver cancer2026
Portal Vein Tumor Thrombus in Hepatocellular Carcinoma: An Immune Sanctuary Driving Immune Exclusion and Therapeutic Resistance.
Review in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Portal vein tumor thrombus (PVTT) is the most common form of macrovascular invasion in hepatocellular carcinoma (HCC) and is associated with poor prognosis, rapid intrahepatic dissemination, and limited responsiveness to systemic therapy. Increasing evidence indicates that PVTT is not merely an intravascular extension of the primary tumor, but rather a biologically distinct and highly adaptive immunosuppressive niche that contributes to immune escape and therapeutic resistance. Summary: This review summarizes current genomic, transcriptomic, single-cell, and spatially resolved evidence regarding the immune landscape of PVTT in HCC. We discuss how early clonal divergence, hypoxia-associated metabolic rewiring, and stromal-vascular remodeling cooperatively shape the PVTT microenvironment. PVTT is characterized by enrichment of suppressive myeloid populations, activation of cancer-associated fibroblast programs, extracellular matrix accumulation, endothelial barriers to immune-cell trafficking, and progressive dysfunction or exclusion of effector lymphocytes. Together, these features establish a strongly immune-excluded and immunosuppressive ecosystem, providing a mechanistic basis for the limited efficacy of immune checkpoint blockade in patients with HCC-PVTT. We further highlight the translational implications of this framework for biomarker development, patient stratification, and rational combination strategies targeting suppressive myeloid and stromal programs, vascular barriers, and metabolic-immune crosstalk. Key Messages: PVTT should be regarded as a distinct immunosuppressive niche rather than a passive vascular extension of the primary tumor. Its immune landscape is shaped by coordinated interactions among tumor evolution, metabolic adaptation, stromal remodeling, and immune dysfunction. A better mechanistic understanding of PVTT may support biomarker-guided stratification and the development of more effective precision therapies for HCC with macrovascular invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.